
## Chiara Corti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2566514/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Therapeutic vaccines for breast cancer: Has the time finally come?. European Journal of Cancer, 2022, 160, 150-174.	2.8	49
2	Targeting brain metastases in breast cancer. Cancer Treatment Reviews, 2022, 103, 102324.	7.7	46
3	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Npj Breast Cancer, 2022, 8, 23.	5.2	67
4	Bystander effect of antibody–drug conjugates: fact or fiction?. Current Oncology Reports, 2022, 24, 809-817.	4.0	35
5	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Frontiers in Molecular Biosciences, 2022, 9, 834651.	3.5	63
6	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opinion on Investigational Drugs, 2022, 31, 593-605.	4.1	31
7	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. European Journal of Cancer, 2022, 166, 202-207.	2.8	4
8	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treatment Reviews, 2022, 106, 102395.	7.7	60
9	Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents Journal of Clinical Oncology, 2022, 40, 3063-3063.	1.6	0
10	Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?. European Journal of Cancer, 2022, 171, 25-42.	2.8	9
11	Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. European Journal of Cancer, 2022, 172, 332-339.	2.8	6
12	Commentary: SARS-CoV-2 vaccines and cancer patients. Annals of Oncology, 2021, 32, 569-571.	1.2	43
13	SARS-CoV-2 vaccines for cancer patients: a call to action. European Journal of Cancer, 2021, 148, 316-327.	2.8	55
14	Antibody–Drug Conjugates for the Treatment of Breast Cancer. Cancers, 2021, 13, 2898.	3.7	34
15	Managing side effects of immune checkpoint inhibitors in breast cancer. Critical Reviews in Oncology/Hematology, 2021, 162, 103354.	4.4	15
16	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. Cancer Treatment Reviews, 2021, 97, 102205.	7.7	21
17	Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals, 2021, 14, 884.	3.8	17
18	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews, 2021, 99, 102253.	7.7	26

CHIARA CORTI

#	Article	IF	CITATIONS
19	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers, 2021, 13, 5829.	3.7	8
20	Novel immune targets for the treatment of triple-negative breast cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 815-834.	3.4	11
21	Adjuvant treatment of early male breast cancer. Current Opinion in Oncology, 2020, 32, 594-602.	2.4	6
22	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 2020, 11, 719.	2.4	67
23	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1461.	4.1	25
24	Tubular Adenoma of the Breast. Encyclopedia of Pathology, 2020, , 379-384.	0.0	0
25	Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?. Advances in Anatomic Pathology, 2019, 26, 270-279.	4.3	29
26	Columnar Cell Lesion and Apocrine Hyperplasia of the Breast: Is There a Common Origin? The Role of Prolactin-induced Protein. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 508-514.	1.2	11
27	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. JNCI Cancer Spectrum, 2018, 2, pky056.	2.9	71
28	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. BMC Cancer, 2018, 18, 935.	2.6	32
29	Tubular Adenoma of the Breast. Encyclopedia of Pathology, 2018, , 1-6.	0.0	Ο
30	Lymphovascular invasion and extranodal tumor extension as risk indicators of breast cancer-related lymphedema Journal of Clinical Oncology, 2018, 36, e12609-e12609.	1.6	0
31	Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. Journal of Visualized Experiments, 2017, , .	0.3	11